To quantifyĬell proliferation, mice were intraperitoneally injected with the Immunostaining was performed on the whole retina at 3 and 7 daysĪfter RVO to evaluate macrophage/microglia responses. Various genes were analyzed by real-time RT-PCR. Time points after RVO, animals were sacrificed and the expression of Laser ophthalmoscopy and optical coherence tomography. Vivo the development of tissue changes by funduscopy, scanning Methods: A complete and permanent occlusion of a retinal vein ofĬ57Bl/6J Rj mice was obtained using 534nm laser. Here, we analyzed the involvement of inflammation in To date, the inflammatory processes that accompanyīRVO and its role in the microvascular remodelling have received May lead to a variable combination of capillary non-perfusion and Purpose: Retinal vein occlusion (RVO) is an important cause ofīlindness because of the subsequent microvascular remodelling that Paris, France 3UPMC UMRS 968, Paris, France. Vision - INSERM U 968, Paris, France 2CHNO des Quinze-Vingts, Lavalette1, 3, Michel Paques1, 2, Florian Sennlaub1, 3. Inflammatory processes in branch retinal vein occlusion in miceĮlisa Dominguez1, 3, Sophie Cavallero1, 3, William Raoul1, 3, Sophie Program Number: 100 Poster Board Number: C0105 With respect to change in IOP especially in Chinese patientsĬonsidered at higher risk for steroid-induced IOP.Ĭommercial Relationships: Timothy L. With similar results compared to DM/T in both a primarily White Group), while in the China study, 19 patients (6 LE/T 13 DM/T)Įxperienced an IOP increase of ≥10 mm Hg over baseline.Ĭonclusions: LE/T was effective in the treatment of lid inflammation Group experienced IOP increases of ≥ 5 mm Hg over baselineĬompared to the LE/T group. In both studies twice as many patients in the DM/T LE/T beginning at day 8 (US study) or Day 3 (China study) Patients treated with DM/T experiencedĪ significant increase in IOP compared to those patients treated with 66.7% for DM/T in the US study and 75.0% for LE/T vs. The reduction in composite blepharitis severity was 68.8% for LE/T Populations with both treatments at each follow-up visit. A significant CFB in blepharitis severity was seen in both Were primarily White (>80%) all patients in the China study wereĬhinese. In the US and China studies, respectively. Patients (178 LE/T, 176 DM/T) were included in the ITT population
Results: A total of 273 patients (136 LE/T, 137 DM/T) and 354 Of AEs, and changes in visual acuity (VA), biomicroscopy, and Hyperemia, lid scaling or crusting, and lid margin hypertrophy, each The primary endpoint in this analysis was the change fromīaseline (CFB) to day 15 in composite blepharitis severity (lid Signs and symptoms were assessed at baseline and on days 3,Ĩ, and 15.
The first study was conductedĪt clinical centers in the US the second study at clinical centers inĬhina. Inīoth studies patients aged ≥18 years withīlepharokeratoconjunctivitis in at least one eye received LE/T orĭM/T administered QID for 2 weeks. Parallel-group clinical trials with similar designs were conducted. Methods: Two multicenter, randomized, investigator-masked, Ophthalmic suspensions for the treatment of lid inflammation across (LE/T) and dexamethasone 0.1%/tobramycin 0.3% (DM/T) Purpose: To compare loteprednol etabonate 0.5%/tobramycin 0.3% Rochester, NY 2Statistics, Bausch & Lomb Incorporated, Rochester, 1MedicalĪffairs, Global Pharmaceuticals, Bausch & Lomb Incorporated, Treatment of Lid Inflammation in Two Populations With Tobradex (dexamethasone 0.1%/tobramycin 0.3%) for the Zylet (loteprednol etabonate 0.5%/tobramycin 0.3%) Compared Program Number: 99 Poster Board Number: C0104 Organizing Section: Physiology/Pharmacology ARVO 2013 Annual Meeting Abstracts by Scientific Section/Group – Physiology/Pharmacology